Kornimate/medical-research-clean huggingface dataset:
application value of targeted nursing based on risk assessment strategies in the treatment of patients with gynecological endocrine disorders

Conditions: Gynecological Endocrine Disorders; Risk Assessment; Targeted Nursing Care; Psychological Support; Quality of Life

Summary: risk-based targeted nursing significantly enhances clinical outcomes, quality of life, and mental health in patients with gynecological endocrine disorders, supporting its broader clinical application.

to evaluate the clinical value of targeted nursing care based on risk assessment in patients with gynecological endocrine disorders. a prospective controlled study was conducted to analyze the clinical data of 84 patients with endocrine disorders and 89 healthy women, focusing on identifying risk factors associated with endocrine disorders and designing corresponding personalized nursing interventions. a total of 154 patients with gynecological endocrine disorders, treated between december 2023 and june 2024, were randomly assigned into a control group (n = 77) and an observation group (n = 77) using a random number table method. the control group received routine nursing care, while the observation group received targeted nursing interventions based on risk assessment strategies in addition to routine care. nursing outcomes, patient satisfaction, quality of life scores, and psychological status-including self-rating anxiety scale (sas) and self-rating depression scale (sds) scores-were compared between the two groups.

Eligibility criteria:
inclusion criteria: clinical diagnosis of gynecological endocrine disorder aged 18-45 years complete clinical data available willing and able to provide informed consent exclusion criteria: severe systemic or psychiatric illness recent major surgery or hormonal/fertility treatment (within 3 months) known hypersensitivity to study medications currently pregnant or breastfeeding participation in another clinical trial within 6 months
increasing use of continuous glucose monitors in publicly-insured youth with type 1 diabetes

Conditions: Type1diabetes

Summary: to use an enhanced continuous glucose monitor (cgm) experience, including an automated cgm-electronic health record (ehr) data integration system, proactive interventions, and gamification techniques, to increase cgm use among publicly-insured youth with type 1 diabetes (t1d).

the investigators will use an automated data integration system to monitor hours per week the cgm is worn and target interventions/troubleshooting techniques as needed. the investigators will use gamification techniques (i.e. ability to gain points and achieve small rewards) to help encourage cgm use and potentially improve glycemic control in this at-risk population.

Eligibility criteria:
inclusion criteria: * type 1 diabetes for more than 6 months * on insulin pump or multiple daily injections without plans to change modality in next 6 months * insured by ccs or medi-cal * receiving care at lucile packard children's hospital or stanford children's health outpatient clinics * english or spanish-speaking exclusion criteria: * major illness or condition that may alter glucose control or ability to complete the study including pregnancy, cystic fibrosis, cancer, liver disease, history of transplant, or hemoglobinopathy * current oral glucocorticoid use * prior use of a cgm system * hemoglobin a1c \ 12% * no wireless internet access
a study comparing two different chemotherapy types in chinese patients with advanced non small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * present with histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer (nsclc) stage iiib or iv. * participants must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug. * female participants must not be pregnant. * no prior systemic chemotherapy for lung cancer. * at least one unidimensionally measurable lesion meeting response evaluation criteria in solid tumors. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate organ function. * prior radiation therapy allowed to \<25% of the bone marrow. * signed informed consent document on file. * estimated life expectancy of greater than or equal to 12 weeks. * participant compliance and geographic proximity that allow adequate follow up. exclusion criteria: * peripheral neuropathy of great than or equal to common terminology criteria for adverse events (ctcae) grade 1. * inability to comply with protocol or study procedures. * a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study. * a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the new york heart association class iii or iv. * second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * documented brain metastases unless the participant has completed successful local therapy for central nervous system metastases and has not taken corticosteroids for at least 4 weeks before enrollment. * presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry. * significant weight loss (that is, greater than or equal to 10%) over the previous 6 weeks before study entry. * concurrent administration of any other anti-tumor therapy. * inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents, such as piroxicam). * inability or unwillingness to take folic acid or vitamin b12 supplementation. * inability to take corticosteroids. * pregnant or breast-feeding. * are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
sensory processing patterns in hearing loss

Conditions: Hearing Loss

Summary: this study aimed to evaluate the sensory processing abilities of adults with acquired hearing loss and to explore the differences in sensory processing between adults with hearing loss and adults with normal hearing. sensory processing functions of 30 adults with acquired hearing loss will be evaluated using the adolescent/adult sensory profile. the data from adults with hearing loss will be compared with data from 30 adults with normal hearing who were similar in gender and age.

this study aims to investigate the sensory processing patterns of adults with hearing loss and compare them with healthy controls. in this study, it was hypothesized that adults with hearing loss, had an abnormal sensory profile like children with hearing loss. participants will consist of individuals between the ages of 18-65 who were taken into audiological evaluation at the outpatient unit of audiology of a hospital and voluntarily agreed to participate in the study. according to the audiological test results, individuals with a pure tone average of more than 25 decibel (db) in the better ear and with less than 10 db difference between the air-bone conduction thresholds will be included in the study group, and those with a pure tone average of 25 db or less in both ears and with less than 10 db difference between the air-bone conduction thresholds will be included in the control group. hearing aid users, those with chronic tinnitus and/or dizziness, and those with major medical disorders and/or handicaps will not be included in the study. in this study, hearing handicap inventory for adults (hhia) and adolescent/adult sensory profile will be used.

Eligibility criteria:
inclusion criteria: * adults with acquired sensorineural hearing loss for study group * adults with normal hearing for control group exclusion criteria: * hearing aid users * adults with chronic tinnitus and/or dizziness * adults with major medical disorders and/or handicap

Keywords: adult hearing loss sensory processing
cortico-saving treatments proposed for clippers: a first cohort

Conditions: CLIPPERS

Summary: the primary objective of this study is to collect information about how clippers patients are currently being treated in france.

this is an observational study. data will be prospectively collected, starting with a detailed baseline description of disease and treatment status, followed by updates everything six months for the next three years.

Eligibility criteria:
inclusion criteria: * patient correctly informed about the study * symptoms and/or clinical signs indicating that the brain stem is affected * mri shows punctate gadolinium highlights and/or curvilinear bridge and/or middle cerebellar peduncles * clinical and radiological cortico sensitivity * if a cerebral biopsy has been performed, presence of a lymphocytic, histiocytic or lympho-hysticytic infiltrate exclusion criteria: * symptoms and/or clinical signs indicating impairment other than the central nervous system * cortical impairment present on mri, microbleeds, stenosis on magnetic resonance angiography, or pacchymeningitis * presence of other diseases that could explain such clinical and radiological signs (see inclusion criteria) * if a cerebral biopsy has been performed, presence of signs of malignancy (eg, clonal proliferation, cellular atypia), vasculitis, granuloma, or demyelination
protein-rich meals to control glucose

Conditions: Overweight; Obesity; Prediabetes; Type 2 Diabetes

Summary: the overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. the specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.

overweight individual with prediabetes and non-insulin treated type 2 diabetes will be recruited for the study. the trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake - a high-protein (hp) breakfast and a high-carb (hc) dinner (hp/hc intervention) vs. a hc breakfast and a hp dinner (hc/hp intervention) - divided by a 4-week wash-out phase. a hp low-carb meal (breakfast or dinner) will contain 35%e protein, 35%e carbs, and 30%e fat, and a hc meal (breakfast or dinner) will contain 10e%protein, 60%e carbs, and 30%e fat.

Eligibility criteria:
inclusion criteria: * prediabetes (fasting blood sugar 100-125 mg/dl) * diabetes type 2 (fasting blood sugar \&gt;126 mg/dl) * overweight and obesity (bmi 25-50 kg/m2) exclusion criteria: * other diabetes types * insulin treatment * shift work * weight changes \&gt;5% within past 3 months * systemic glucocorticoid therapy * systemic infections * severe anemia * high blood pressure (\&gt;180/110 mmhg) * endocrinologic, liver and heart disorders * immune diseases * thyroid dysfunction * heart attack or stroke * cancer in the last 2 years * eating disorders, food intolerance/allergy, addiction disorders, digestive disorders intestinal, liver, cardiovascular diseases * hereditary or acquired coagulation disorders * non-interruptible intake of blood thinners (anticoagulants) * specific diets, intermittent fasting * pregnancy or breastfeeding * severe internal or psychiatric disorders or other conditions and drugs therapy that might influence the outcome of the study

Keywords: glucose overweight obesity prediabetes type 2 diabetes metabolism chrononutrition macronutrient composition high-protein high-carb isocaloric diet prevention and treatment of type 2 diabetes
evaluation of indocyanine green-guided systematic pelvic lymphadenectomy in endometrial and cervical cancer

Conditions: Endometrial Cancer; Cervical Cancer

Summary: the lymph nodes involvement is one of the most important prognostic factors in endometrial (ec) and cervical cancer (cc). indeed, the lymph node involvement in cancer patients modifies the international federation of gynecology and obstetrics (figo) stage and plays a pivotal role in the choice of the adjuvant therapy. since the modern imaging techniques are not yet able to accurately detect lymph nodes metastasis, pelvic systematic lymphadenectomy has still an important role and it still represents the gold standard in ec and cc. the sentinel lymph node (sln) biopsy, which is a standard practice in breast cancer and melanoma, is often used in some early stage gynaecological cancers such as ec and cc. indocyanine green (icg) is the most used tracer for the detection of sln in gynaecological cancer, especially in laparoendoscopic setting. icg allows a complete visualization of the lymphatic drainage and, for this reason, it may be used even in systematic pelvic lymphadenectomy to guide the surgeon during the procedure. several studies have demonstrated an advantage of the icg-guided lymphadenectomy in other types of cancers, showing a higher number of lymph nodes removed with this technique when compared to standard lymphadenectomy (without icg). to date, there is no published study about icg-guided systematic pelvic lymphadenectomy in ec and cc. in this scenario, the aim of this study will be to compare systematic icg-guided pelvic lymphadenectomy and standard lymphadenectomy in ec and cc.


Eligibility criteria:
inclusion criteria: * women affected by endometrial or cervical cancer * laparoscopic/robotic surgical approach with systematic pelvic lymphadenectomy. exclusion criteria: * women undergoing open surgery (laparotomy) for the surgical management of endometrial or cervical cancer.

Keywords: indocyanine green pelvic lymphadenectomy
multilevel system intervention based on information platform to reduce ischemic stroke recurrence rate

Conditions: Acute Ischemic Stroke; Stroke Recrudescence; Quality Improvement

Summary: a prospective, multicenter and cluster randomised controlled trial will be conducted, using hospital as randomisation unit. hospitals in zhejiang province, china, will be randomised into two arms (1:1): an intervention arm and a control arm. hospitals in the intervention arm will receive a multilevel system intervention based on information platform, whereas hospitals in the control arm will receive no intervention. the randomisation will be conducted after baseline data collection. the following baseline data will be used for randomisation match: hospital classification, beds in stroke centre, and the number of acute ischemic stroke (ais) patients within 7 days of stroke onset. hospitals with \<250 ais cases per year will be excluded from the study. the primary outcome will be difference between intervention arm and control arm in the one-year stroke recurrence rate on the follow-up stage (post-intervention).


Eligibility criteria:
inclusion criteria: * patients of 18 years or older. * patients admitted with neurological deficit consistent with ischemic stroke within 7 days of of symptoms onset. (\*symptom onset is defined by the "last seen normal" principle) * confirmation of new ischemic stroke by objective modality of ct scan and mri (had relevant lesions on dwi). * informed consent from patient or legally authorised representative (primarily spouse, parents, adult children, otherwise indicated). exclusion criteria: * patients refuse to participate in this study. * patients who losing his medical record of having the incomplete medical record
dosage of serum tryptase levels in a population of premature newborns to evaluate mast cell activity

Conditions: Premature Newborns

Summary: compare serum tryptase levels of premature babies (\<37 weeks of amenorrhea) to children born at full term. study the evolution of serum tryptase levels in premature babies(\<37 weeks of amenorrhea). study the relationship between the onset of infectious complications, mainly the type of necrotizing enterocolitis seen in premature babies (\<37 weeks of amenorrhea) and the evolution profile of serum tryptase levels.

it seems appropriate to believe that prematurity associated or not with a genetic-related sensitivity, involving several signaling pathways, makes children more vulnerable to different environmental, infectious factors that could trigger the different pathologies of premature babies. mast cell, via its mediators, seems to play a key role. dosage of serum tryptase levels which is easily accessible and the work by vitte let us imagine that the younger the child, the greater the mast cell expression, thus opening a capital pathway in the comprehension of immune system phenomena in premature babies and investigators can hope that by performing regular workups of serum tryptase levels, investigators could validate that some premature babies will express this activity in a more important manner. the relationship to eventual pathological phenomena such as necrotizing enterocolitis, but also bronchopulmonary dysplasia could then be highlighted.

Eligibility criteria:
inclusion criteria "patients" : * all premature babies (\<37 weeks of amenorrhea) * managed in the first 24 hours of life at the reims university hospital * parents accepted to participate in the research - social security card inclusion criteria "controls" : * children born full term, just after each "patient" child included * managed in the first 24 hours of life at the reims university hospital * parents accepted to participate in the research. exclusion criteria "patients" and "controls" * not managed in the first 24 hours of life at the reims university hospital, * person, who has parental authority, protected by law, * newborns with a life and death emergency in the first 24 h of life, * person, who has parental authority, under age 18
primary prevention of sudden cardiac death (prev-death)

Conditions: Chronic Heart Failure

Summary: the efficacy of implantable cardioverter-defibrillators (icd) in primary prevention of sudden cardiac death (scd) is well demonstrated but pivotal studies have been published more than 10 years ago and implantation's conditions tend to change.

the clinical efficacy of implantable cardioverter defibrillator (icd) as method of primary prevention of sudden cardiac death (scd) is well demonstrated today. unfortunately, selection criteria of patients deemed at risk lacks of specificity. for asymptomatic patients with a left ventricular dysfunction (lvef), current guidelines support implantation of icd if the lvef is ≤35%. this target population corresponds to the one studied in the sudden cardiac death in heart failure trial (scd-heft). this trial is 10 years old. the proportion of patients with lvef \> 30% was low (17%) and the analysis of this subgroup showed no decrease in mortality (hazard ratio = 1.08 \[0.57-2.07\]). that is why the usefulness of icd in this segment of the population remains a subject of controversy. moreover, scd-heft did not offer resynchronization therapy despite the fact that more than 40% of patients included had a qrs signal duration ≥120ms. conditions for implantation have since changed considerably. the "routine" nature of the implantation procedure and the desire to maximize patient's protection leads us to address for an implantation more easily. as for the resynchronization, it must be attempted in patients with severe heart failure, lvef ≤35% and qrs sufficiently prolonged. this suggests that the implanted population is very different nowadays from those from the pivotal studies in terms of mean lvef and implanted material. however, these two factors are significantly correlated with the risk of scd... therefore, the analysis was done on samples of patients who received icd in primary prevention setting. this study focused on the effect of resynchronization and lvef at implantation and the subsequent outcome. the results were broadly compared with those of scd-heft.

Eligibility criteria:
inclusion criteria: * primo-implantation and primary prevention in new york heart association (nyha) ii or iii chronic heart failure due to ischemic or non ischemic causes and lvef ≤35% exclusion criteria: * cardiomyopathy other than dilated cardiomyopathy such as hypertrophic cardiomyopathy, congenital or valvular heart disease * patients with nyha class i and iv heart failure
multi-center clinical observation of a new treatment method based on the pathogenesis of obstructive prostatitis

Conditions: Chronic Prostatitis

Summary: multi-center clinical observation of a new treatment method based on the pathogenesis of obstructive prostatitis

1. study purpose: to investigate the therapeutic effect of transurethral dilation of prostate with a columnar balloon on patients with chronic obstructive prostatitis 2. study design: a randomized, controlled, multi-center clinical trial 3. study subjects: patients with chronic obstructive prostatitis 4. number of subjects: 180 5. surgery treatments: test group: patients will receive a surgery: transurethral dilation of prostate with a columnar balloon. control group: patients will receive a surgery: transurethral incision of bladder neck.

Eligibility criteria:
inclusion criteria: 1. older than 35 years old, urinary obstruction is clear; 2. the total score of chronic prostatitis symptoms index (cpsi) is greater than 14 points, and the severity of symptoms is greater than 9 points; 3. maximum urine flow rate is less than 15 ml/s; 4. cystoscopy and pathological biopsy confirmed the presence of bladder neck fibrosis, bladder trabeculae formation; 5. other conservative treatments are ineffective or ineffective, and drug treatment is not effective for more than 6 months; 6. voluntarily participated in this clinical trial, complied with the requirements of this study and signed the informed consent form. exclusion criteria: 1. urinary tract infection, urinary tumor, history of intestinal inflammatory disease; 2. neurogenic bladder; 3. history of pelvic radiation therapy or chemotherapy; 4. psa is abnormal; 5. urethral stricture, history of bladder or prostate surgery; 6. the investigator determined that it is not suitable for this clinical trial.

Keywords: chronic prostatitis
soccer play in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: 1. to figure out the effect of soccer play (once a week for 8 weeks) on pulmonary function in children with cerebral palsy 2. to find out if the leisure activity (soccer) increase the quality of life, motor function, gait function etc.. 3. safety of soccer play in children with cerebral palsy

1. 1 hr of play once a week for 8 weeks of soccer program was done in the experimental group. 2. both the experimental and control group were children with ambulatory cerebral palsy aged 5 to 12 years. 3. several outcomes were measured before and after the program * pulmonary function test including fvc, fev1 * gmfm-88, pbs, walking test, muscle power sprint test, timed up and go, gait parameters * child health questionnaire parent form 50 (chq-pf50) * kidscreen 4. an accelerometer was worn before the program and during the program for a week (experimental group only)

Eligibility criteria:
inclusion criteria: * children with cerebral palsy * gmfcs level i-ii * 5-12 years old exclusion criteria: * acute disease, less than 6 months from the surgery * the behavioral or psychiatric problem that hinders group activity * intellectual disability to do the questionnaire * who do not participate in the class well (absent more than 3 times)

Keywords: cerebral palsy